{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adenosine+arm&page=5",
    "query": {
      "intervention": "Adenosine arm",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 105,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adenosine+arm&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adenosine+arm&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T18:12:47.020Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03726879",
      "title": "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 454,
      "start_date": "2019-01-11",
      "completion_date": "2023-08-24",
      "has_results": true,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 3,
      "location_summary": "Kansas City, Missouri • New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03726879"
    },
    {
      "nct_id": "NCT03190967",
      "title": "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Brain Metastasis",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "T-DM1",
          "type": "DRUG"
        },
        {
          "name": "TMZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-04-18",
      "completion_date": "2023-06-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190967"
    },
    {
      "nct_id": "NCT05377424",
      "title": "Adenosine 2A Receptor Antagonism and AIH in ALS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ALS"
      ],
      "interventions": [
        {
          "name": "Consume 20mg of istradefylline",
          "type": "DRUG"
        },
        {
          "name": "Low Oxygen therapy",
          "type": "OTHER"
        },
        {
          "name": "Placebo counterpart to the istradefylline drug",
          "type": "DRUG"
        },
        {
          "name": "SHAM counterpart to low oxygen therapy.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-06-21",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Jacksonville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377424"
    },
    {
      "nct_id": "NCT07175441",
      "title": "Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "RBS2418",
          "type": "DRUG"
        },
        {
          "name": "STRIDE (durvalumab + tremelimumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Riboscience, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2026-04-10",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Nashville, Tennessee • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07175441"
    },
    {
      "nct_id": "NCT01307475",
      "title": "Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Arthrogryposis",
        "Craniofacial Abnormalities",
        "Posttraumatic Stress Disorder",
        "Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "PTSD Checklist-Specific",
          "type": "OTHER"
        },
        {
          "name": "Modified Flanagan Quality of Life Scale",
          "type": "OTHER"
        },
        {
          "name": "Center for Epidemiologic Studies Depression Scale",
          "type": "OTHER"
        },
        {
          "name": "Functional Enquiry Form",
          "type": "OTHER"
        },
        {
          "name": "Strength, Joint ROM, Girth and Length Measurements",
          "type": "OTHER"
        },
        {
          "name": "Study Physical Examination",
          "type": "OTHER"
        },
        {
          "name": "PTSD, Depression, and FSS-Focused Examination",
          "type": "OTHER"
        },
        {
          "name": "Freeman-Sheldon Specific Quality of Life Survey",
          "type": "OTHER"
        },
        {
          "name": "Lactate, Glucose, and Adenosine Triphosphate Blood Levels",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Freeman-Sheldon Research Group, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 6,
      "start_date": "2011-02",
      "completion_date": "2017-04-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 1,
      "location_summary": "Buckhannon, West Virginia",
      "locations": [
        {
          "city": "Buckhannon",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307475"
    },
    {
      "nct_id": "NCT01165931",
      "title": "Coronary Vasomotor Response After Riociguat Exposure",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Riociguat (BAY63-2521)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-05",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-10-23",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01165931"
    },
    {
      "nct_id": "NCT06644573",
      "title": "Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Insomnia",
        "Sleep Deprivation",
        "REM Behavior Disorder",
        "REM Sleep Behavior Disorder",
        "REM Sleep Measurement",
        "Insomnia",
        "Insomnia Related to Specified Disorder",
        "Insomnia Due to Other Mental Disorder",
        "Insomnia Comorbid to Psychiatric Disorder",
        "Insomnia Due to Anxiety and Fear",
        "Insomnia Related to Another Mental Condition",
        "Insomnia Disorders",
        "Idiopathic Hypersomnia",
        "Sleep Disorders, Circadian Rhythm",
        "Post Trauma Nightmares",
        "PTSD - Post Traumatic Stress Disorder",
        "Sleep Quality",
        "Anesthesia",
        "Anxiety",
        "Depression",
        "Mental Health",
        "Alzheimer Disease or Associated Disorder",
        "Parkinsons",
        "Circadian Rhythm",
        "Circadian Dysregulation",
        "PTSD",
        "Post-Traumatic",
        "Post-Traumatic Stress Disorder Complex",
        "Military Combat Stress Reaction",
        "Sleep",
        "Military Activity",
        "Veterans",
        "Shift Work Sleep Disorder",
        "Menopause Related Conditions",
        "Pain",
        "Cancer Pain",
        "Athletes"
      ],
      "interventions": [
        {
          "name": "PROSOMNIA Sleep Therapy™ (PSTx)",
          "type": "PROCEDURE"
        },
        {
          "name": "Anesthesia-Induced Sleep Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Diprivan (propofol), Astra-Zeneca",
          "type": "DRUG"
        },
        {
          "name": "Continuous EEG Monitoring",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Nyree Penn",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-11-01",
      "completion_date": "2026-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 1,
      "location_summary": "Aventura, Florida",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06644573"
    },
    {
      "nct_id": "NCT03150667",
      "title": "Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Ticagrelor",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "North Texas Veterans Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2017-04-10",
      "completion_date": "2020-04-30",
      "has_results": false,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Dallas, Texas",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03150667"
    },
    {
      "nct_id": "NCT03012672",
      "title": "Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia of Ambiguous Lineage",
        "Acute Myeloid Leukemia",
        "Myeloid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mitoxantrone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2016-12-30",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2022-03-08",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03012672"
    },
    {
      "nct_id": "NCT04266249",
      "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Lumpectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Mastectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2175,
      "start_date": "2020-03-13",
      "completion_date": "2038-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-15T18:12:47.020Z",
      "location_count": 999,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04266249"
    }
  ]
}